(Reuters) – Teva Pharmaceutical Industries Ltd (TEVA.TA) (TEVA.N) is close to a deal to sell its women’s health assets outside the United States to private equity firm CVC Capital Partners, the Fly reported, citing Bloomberg.
The assets could be valued at about $800 million, according to the Bloomberg report. (bit.ly/2y03sQx)
Israel-based Teva, the world’s largest maker of generic drugs, has been looking at divestures to help pare its $35 billion debt pile.
The company on Monday agreed to sell its contraceptive brand, Paragard, a part of its women’s health business, to a unit of Cooper Cos (COO.N) for $1.1 billion, on a day the company named industry veteran Kare Schultz as CEO.
CVC Capital was not immediately available for comment, while Teva said it does not respond to market rumors.